Please login to the form below

Not currently logged in
Email:
Password:

Halozyme Therapeutics

This page shows the latest Halozyme Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Halozyme to resume pancreatic cancer study

Halozyme to resume pancreatic cancer study

FDA says PEGPH20 trial can continue. There was relief for Halozyme Therapeutics after it was told it can resume a clinical study investigating a potential treatment for pancreatic cancer. ... With the trial now back underway, Halozyme said it intends to

Latest news

  • Halozyme halts pancreatic cancer trial Halozyme halts pancreatic cancer trial

    The biopharma company is investigating PEGPH20’s links to blood clot. Halozyme Therapeutics has paused a phase II trial of its investigational pancreatic cancer drug in order to assess the ... As for the fate of PEGPH20, Halozyme's CEO Dr Helen Torley

  • Baxter re-files HyQvia for immunodeficiency in US Baxter re-files HyQvia for immunodeficiency in US

    HyQvia - which uses delivery technology developed by Halozyme Therapeutics - is a combination of human normal immunoglobulin (IG) and recombinant human hyaluronidase which can be delivered by subcutaneous injection every three to ... Meanwhile, for

  • Roche wins EU approval for injectable Herceptin Roche wins EU approval for injectable Herceptin

    Roche developed subcutaneous Herceptin using recombinant human hyaluronidase technology developed by US-based biopharma company Halozyme Therapeutics.

  • Drug delivery

    Halozyme receives $9m upfront and up to $54m in development and regulatory milestones. ... Commercialisation. 134. Halozyme Therapeutics/Intrexon Corp. rHuPH20 enzyme drug delivery. technology for COPD and genetic emphysema.

  • New leadership for Halozyme

    Halozyme Therapeutics, the San Diego-based enzyme therapy developer that in October realigned its research priorities and cut its workforce by 25 per cent, has appointed Gregory I Frost to serve ... Halozyme Therapeutics, whose partners include Roche and

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Pharma deals in June 2015 Pharma deals in June 2015

    Acquisition - company. 1, 470. Halozyme Therapeutics/ AbbVie. ENHANZE platform technology to improve sc delivery (up to 9 targets). ... NewCo formation, collaboration. 760. Unum Therapeutics/ Seattle Genetics. Antibody-coupled T-cell receptor technology

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Expansion of collaboration/ amended agreement. 675. Halozyme Therapeutics / J&J. ENHANZE rHuPH20 delivery technology for up to 5 targets. ... Licence - amended agreement. †300. Spark Therapeutics / Pfizer. Multiple haemophilia B gene therapy products

  • Pharma deals during December 2014 Pharma deals during December 2014

    Switching to drug delivery technologies, J&J/Janssen entered into a global licence with Halozyme Therapeutics to access Halozyme's ENHANZE technology, which is designed to enable subcutaneous administration of injectable ... Subcutaneous formulations of

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

DNA
Why precision medicine demands precision engagement
The speed of innovation brings its own challenges, says cloud computing expert...
Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...

Infographics